Seeking Alpha

More on AstraZeneca (AZN +1.2% in London) Q3: Pretax profits $2B vs $4.2B, with performance hurt...

More on AstraZeneca (AZN +1.2% in London) Q3: Pretax profits $2B vs $4.2B, with performance hurt by patent expiries. Sales breakdown: Seroquel IR (Schizophrenia) -83% at constant exchange rates to $169M, Nexium (ulcers) -6% to $995M, Arimidex (cancer) -22% to $130M, Crestor (cholesterol) -3% to $1.54B. Reiterates FY EPS forecast of $6-$6.30 vs $7.28 in 2011.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|